Cabazitaxel Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 60 mg/1.5 mL
Reference Brands: Jevtana®(US & EU)
Category: Oncology Cancer Care
Cabazitaxel is available in Injection and strengths such as 60 mg/1.5 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Cabazitaxel is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Cabazitaxel can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Cabazitaxel, a next-generation taxane chemotherapy agent, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), especially in patients previously treated with docetaxel. Marketed under the brand Jevtana® in the US and EU, it is available as a 60 mg/1.5 mL injectable concentrate, requiring dilution before intravenous infusion. Cabazitaxel inhibits microtubule depolymerization, disrupting cancer cell mitosis. Manufactured under strict GMP standards, Cabazitaxel is a key product for B2B pharma partners focused on oncology and urology segments. It presents reliable commercial opportunities in highly regulated markets across Europe and North America.
Frequently Asked Questions
Related Products
Atezolizumab
Strength:
1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength:
120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength:
12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers
